Loading news...
Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock traders bought 12,429 call options on the company. This is an increase of 579% compared to the typical volume of 1,830 call options. Wall Street Analysts Forecast Growth Several equities analysts have recently weighed in
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Valuation and Earnings This table compares TransCode
NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees.
The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $2.26. This compares to a loss of $3.6 per share a year ago.
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Total Revenue was $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $115 Million for Full Year 2025 – – Company Provides Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.
-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
NEWTON, Mass., Feb. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired employees.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $6.65 and traded as low as $6.36. Karyopharm Therapeutics shares last traded at $6.65, with a volume of 318,465 shares trading hands. Wall Street
Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Preliminary Unaudited Full Year 2025 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $115 Million, Respectively – NEWTON, Mass., Jan. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2025 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2025 achievements and 2026 objectives.
NEWTON, Mass., Jan. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,533 restricted stock units (RSUs) to two newly-hired employees.
NEWTON, Mass. , Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m.
NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock and an aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees.
NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 37th Annual Healthcare Conference in a fireside chat on Thursday, December 4, 2025 at 10:30 a.m.
NEWTON, Mass. , Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted stock units (RSUs) to one newly-hired employee.
Karyopharm Therapeutics Inc. ( KPTI ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Brendan Strong - SVP of Investor Relations & Corporate Communications Richard Paulson - President, CEO & Director Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Sohanya Cheng - Executive VP, Chief Commercial Officer & Head of Business Development Lori Macomber - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank PLC, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Chang - Leerink Partners LLC, Research Division Presentation Operator Good morning.
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.
-- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass.